Antipsychotic Increase Could Harm Mentally Ill TD Patients
An 18-year cohort study of severely mentally ill Afro-Caribbeans reported conflicting advisory from current tardive dyskinesia standards.
Rare Genetic Variant Linked to MS Risk, Vitamin D Levels
A rare variant of CYP2R1 doubles the risk of low vitamin D and increases MS risk by 40%.
Long-term Ingrezza Found Safe for Tardive Dyskinesia
Researchers gauged 3 pooled study results to consider the safety and tolerability of marketed valbenazine for TD.
Biomarkers Aid in Diagnosis, Prognosis of Early Multiple Sclerosis
Serum levels of interleukin-7 and C-X-C motif chemokine ligand 10 appeared to provide the most accurate means of identifying large differences in disease risk.
Study: Controlling TD in Mood Disorder Requires Long-Term Valbenazine Therapy
After the 4-week washout phase, scores indicated re-emergence of TD.
Benefits, Risks of Immunomodulatory MS Drugs Assessed
According to the review, understanding the basis for the neurodegeneration of MS is the next big challenge for the treatment of the disease.
In Movement Disorders, Benefits and Risks Depend on Tetrabenazine Isomer
Until recently, researchers were able to measure only the total concentrations of alpha and beta isomers instead of quantifying each of the 4 isomers.
Experts Share Insights on New Developments in Tardive Dyskinesia
Valbenazine a breakthrough for patients treated empirically to date.
Houston Team Reviews Prevention and Treatment of Tardive Dyskinesia
A highly effective antipsychotic with no major motor side effects is needed.
Review Helps Doctors Decide How Much to Push for Valbenazine for TD
Determining optimal dose, full benefits & risks requires long-term clinical use.
FDA Approvals Offer Choice of VMAT-2 Inhibitors for Tardive Dyskinesia
Studies show rates of depression and suicidality similar to those for placebo.
Eye Care Professionals Differ in Advice for AMD Patients
Optometrists were more likely to recommend supplements with macular carotenoids, while ophthalmologists recommended supplements with the AREDS formula of vitamins and minerals.
Experts Detail Stepwise Approach to Treating Tardive Dyskinesia
Treatment with the new VMAT-2 inhibitors is likely to transform TD management.
Subthalamic Deep Brain Stimulation Improves Tardive Dystonia Long-Term
Decreases in motor and disability scores after surgery persisted for years.
Elovanoids Provide Novel Therapeutic Approach to Retinal Degeneration
These mediators may help maintain retinal functional integrity, preserve vision.
Tardive Dyskinesia Highly Prevalent with Certain Non-antipsychotic Medication
In Treatment-Resistant AMD, Contrast Sensitivity Improved after Switch from Ranibizumab to Aflibercept
Higher log contrast sensitivity correlated with decrease in central retinal thickness.
Converting from Tetrabenazine to Deutetrabenazine for HD Chorea Appears Safe
Trial patients' total maximal chorea score improved by 2 points in 8 weeks.
KINECT Analysis Finds Differently Diagnosed TD Affects Patients Differently
Patients' tongues are more affected in mood disorders than in schizophrenia.
Oral Drug X-82 Shows Promise for Wet Age-Related Macular Degeneration
After 24 weeks, 96% of study patients had stable or better visual acuity than they did at baseline.
Sublingual Apomorphine Dose Needed Independent of Parkinson's Severity
APL-130277 began relieving “off” episodes 5–12 minutes after administration.
AIM-TD Study: Deutetrabenazine Fixed Doses Reduced Tardive Dyskinesia
The positive results came from a 3 fixed-dose Phase III trial involving nearly 300 patients.
Imaging Studies Explore Whether Parkinson's Disease Begins in Gut
Disease may start in its autonomic nerve endings and ascend to the brainstem.
No Sign of New Movement Disorders from Long-term Valbenazine for TD
85% of subjects also took antipsychotic medications, usually atypical agents.
Minimal Clinically Important Difference in TD Scale Score Identified
A 3-point median score change may be considered an MCID for a robust response.
Study: SC Apomorphine Reduced "Off" Time in Advanced Parkinson's
The TOLEDO study noted it also increased “on” time without troublesome dyskinesia.
Gene Therapy for Huntington's Disease Begins Moving from Lab to Clinic
No evidence of adverse events or significant safety concerns has surfaced.
Imaging Studies Clarify Pathophysiology of Movement Disorders
The development was presented by David Eidelberg, MD, at the 21st International Congress of Parkinson's Disease and Movement Disorders.
Rating Scales Show Gel Improves Daily Living Experience in Parkinson's
Scores on key scales improved 20%–28% after 1 year of jejunal levodopa/carbidopa.
Clinical Outcome Assessments Gain Approval for Movement Disorder Drugs
Patient- and clinician-rated outcomes were keys in supporting labeling claims.
2 Clarke Drive Cranbury, NJ 08512